Essential role of nuclear factor-{kappa}B for NADPH oxidase activity in normal and anhidrotic ectodermal dysplasia leukocytes

Blood

Volumn 112, Issue 4, 2008, Pages 1453-1460

  Luengo Blanco, Marcos ^a   Prando, Carolina ^a   Bustamante, Jacinta ^b   Aragão Filho, Walmir Cutrim ^c   Pereira, Paulo Vitor Soeiro ^c   Rehder, Jussara ^a   Padden, Carolyn ^d   Casanova, Jean Laurent ^b   Newburger, Peter E ^d   Condino Neto, Antonio ^a,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b IMAGINE INSTITUTE   (France)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; ZYMOSAN; CYBB PROTEIN, HUMAN; MEMBRANE PROTEIN; NEUTROPHIL CYTOSOLIC FACTOR 1;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN U937; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; CYBA GENE; CYBB GENE; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; GENE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOHIDROTIC ECTODERMAL DYSPLASIA; IMMUNE DEFICIENCY; LEUKOCYTE; NCF1 GENE; NCF2 GENE; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST; X CHROMOSOME LINKED DISORDER; CELL CULTURE; CELL LINE; ECTODERMAL DYSPLASIA; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CELL LINE, TRANSFORMED; CELLS, CULTURED; ECTODERMAL DYSPLASIA; GENE EXPRESSION; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; LEUKOCYTES; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; NF-KAPPA B; PHAGOCYTES; PHAGOCYTOSIS;

EID: 51649097967     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-07-099267     Document Type: Article

References (46)

1. Babior BM. NADPH oxidase. Curr Opin Immunol. 2004;16:42-47.
2. Nauseef WM. Assembly of the phagocyte NADPH oxidase. Histochem Cell Biol. 2004;122: 277-291.
3. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin Immunol. 2003;15:578-584.
4. Rae J, Newburger PE, Dinauer MC, et al. X-Linked chronic granulomatous disease: Mutations in the CYBB gene encoding the gp91 -phox component of respiratory-burst oxidase. Am J Hum Genet. 1998;62:1320-1331.
5. Skalnik DG, Dorfman DM, Perkins AS, et al. Targeting of transgene expression to monocyte/macrophages by the gp91 -phox promoter and consequent histiocytic malignancies. Proc Natl Acad Sci U S A. 1991 ;88:8505-8509.
6. Lindsey S, Huang W, Wang H, et al. Activation of SHP2 protein-tyrosine phosphatase increases HoxA10-induced repression of the genes encoding gp91 (PHOX) and p67(PHOX). J Biol Chem. 2007;282:2237-2249.
7. Bei L, Lu Y, Eklund EA. HOXA9 activates transcription of the gene encoding gp91 Phox during myeloid differentiation. J Biol Chem. 2005;280: 12359-12370.
8. Skalnik DG. Transcriptional mechanisms regulating myeloid-specific genes. Gene. 2002;284:1- 21.
9. Li SL, ValenteAJ, Zhao SJ, Clark RA. PU. 1 is essential for p47(phox) promoter activity in myeloid cells. J Biol Chem. 1997;272:17802-17809.
10. Marden CM, Stefanidis D, Cunninghame-Graham DS, Casimir CM. Differentiation-dependent up- regulation of p47(phox) gene transcription is associated with changes in PU. 1 phosphorylation and increased binding affinity. Biochem Biophys Res Commun. 2003;305:193-202.
11. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene. 2006;25:6706-6716.
12. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionary conserved mediators of immune responses. Annu Rev Immunol. 1998:16: 225-260.
13. Pennington KN, Taylor JA, Bren GD, Paya CV. IkappaB kinase-dependent chronic activation of NF-kappa B is necessary for p21(WAF1/Cip1) inhibition of differentiation-induced apoptosis of monocytes. Mol Cell Biol. 2001 ;21:1930-1941.
14. Moynagh PN. The NF-kappaB pathway. J Cell Sci. 2005;118:4589-4592.
15. D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B (NF-B): an emerging theme in anti-inflammatory therapies. Mol Interv. 2002;2:22-35.
16. Condino-Neto A, Whitney C, Newburger PE. Dexamethasone but not indomethacin inhibits human phagocyte nicotinamide adenine dinucleotide phosphate oxidase activity by down-regulating expression of genes encoding oxidase components. J Immunol. 1998;161:4960-4967.
17. Gauss KA, Nelson-Overton LK, Siemsen DW, et al. Role of NF-kappaB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-alpha. J Leukoc Biol. 2007;82: 729-741.
18. Anrather J, Racchumi G, ladecola C. NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91 phox. J Biol Ghem. 2006:281:5657-5667.
19. Lien LL Lee YS, Orkin SH. Regulation of the my-eloid-cell-expressed human gp91 -phox gene as studied by transfer of yeast artificial chromosome clones into embryonic stem cells: Suppression of a variegated cellular pattern of expression requires a full complement of distant cis elements. Mol Cell Biol. 1997;17:2279-2290.
20. Asin S, Taylor JA, Trushin S, Bren G, Paya GV. Ikappakappa mediates NF-kappaB activation in human immunodeficiency virus-infected cells. J Virol. 1999;73:3893-3903.
21. Pahl HL Krauss B, Schulze-Osthoff K, et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF- kappaB. J Exp Med. 1996;183:1829-1840.
22. 558 content of human Epstein-Barr-virus-transformed B lymphocytes correlate with expression of genes encoding components of the oxidase system. Arch Biochem Biophys. 1998;360:158-164.
23. Volkman DJ, Buescher ES, Gallin Jl, Fauci AS. B cell lines as models for inherited phagocytic diseases: superoxide generation in chronic granulomatous disease and granules in Chediak- Higashi syndrome. J Immunol. 1984; 133:3006- 3009.
24. Dusi S, Nadalini KA, Donini M, et al. Nicotinamide-adenine dinucleotide phosphate oxidase assembly and activation in EBV-t ran stormed B lymphoblastoid cell lines of normal and chronic granulomatous disease patients. J Immunol. 1998;161:4968-4974.
25. Agudelo-Flórez P, Prando-Andrade CG, Lopez JA, et al. Chronic granulomatous disease in Latin American patients: clinical spectrum and molecular genetics. Pediatr Blood Cancer. 2006;46:243-252.
26. Chanock SJ, Barrett DM, Curnutte JT, Orkin SH. Gene structure of the cytosolic component phox-47 and mutations in autosomal recessive chronic granulomatous disease. Blood. 1991 ;78: 165a.
27. Döffinger R, Smahi A, Bessia C, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet. 2001 ;27:277-285.
28. Dupuis-Girod S, Corradini N, Hadj-Rabia S, et al. Osteopetrosis, lymphedema, anhidrotic ectodermal dysplasia, and immunodeficiency in a boy and incontinentia pigmenti in his mother. Pediatrics. 2002:109:e97.
29. Dupuis-Girod S, Cancrini C, Le Deist F, et al. Successful allogeneic hemopoietic stem cell transplantation in a child who had anhidrotic ectodermal dysplasia with immunodeficiency. Pediatrics. 2006;118:e205-e211.
30. 30.Courtois G, Smahi A, Reichenbach J, et al. Ahy- permorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplalia and T cell immunodeficiency. J Clin Invest. 2003;112:1108-1115.
31. Condino-Neto A, Newburger PE. Interferon- gamma improves splicing efficiency of CYBB gene transcripts in an interferon-responsive variant of chronic granulomatous disease due to a splice site consensus region mutation. Blood. 2000;95:3548-3554.
32. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983;11:1475-1489.
33. Nishida S, Yoshida LS. ShimoyamaT, et al. Fungal metabolite gliotoxin targets flavocytochrome b558 in the activation of the human neutrophil NADPH oxidase. Infect Immun. 2005;73:235-244.
34. Nishikomori R, Akutagawa H, Maruyama K, et al. X-linked ectodermal dysplasia and immunodeficiency caused by reversion mosaicism of NEMO reveals a critical role for NEMO in human T-cell development and/or survival. Blood. 2004;103: 4565-4572.
35. Kim S, La Motte-Mohs RN, Rudolph D, Zuniga- Pflucker JC, Mak TW. The role of nuclear factor- kappaB essential modulator (NEMO) in B cell development and survival. Proc Natl Acad Sci USA. 2003;100:1203-1208.
36. Puel A, Picard C, Ku CL, Smahi A, Casanova JL. Inherited disorders of NF-kappaB-mediated immunity in man. Curr Opin Immunol. 2004;16:34-41.
37. Puel A, Reichenbach J. Bustamante J, et al. The NEMO mutation creating the most-upstream premature stop codon is hypomorphic because of a reinitiation of translation. Am J Hum Genet. 2006; 78:691-701.
38. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease-Report on a national registry of 368 patients. Medicine. 2000;79: 155-169.
39. Filipe-Santos O, Bustamante J, ChapgierA, et al. Inborn errors of IL-12/23-and I FN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol. 2006;18:347-361.
40. Frix CD, III, Branson DM. Acute miliary tuberculosis in a child with anhidrotic ectodermal dysplasia. Pediatr Dermatol. 1986;3:464-467.
41. Alcaïs A, Fieschi C, Abel L, Casanova JL. Tuberculosis in children and adults: two distinct genetic diseases. J Exp Med. 2005;202:1617-1621.
42. Lau YL, Chan GC, Ha SY, Hui YF. Yuen KY. The role of phagocytic respiratory burst in host defense against Mycobacterium tuberculosis. Clin Infect Dis. 1998;26:226-227.
43. Movahedi M, Aghamohammadi A, Rezaei N, et al. Chronic granulomatous disease: a clinical survey of 41 patients from the Iranian primary immunodeficiency registry. Int Arch Allergy Immunol. 2004;134:253-259.
44. Bustamante J, Aksu G, Vogt G, et al. BCG-osis and tuberculosis in a child with chronic granulomatous disease. J Allergy Glin Immunol. 2007; 120:32-38.
45. Barese C, Copelli S, Zandomeni R, et al. X-linked chronic granulomatous disease: first report of mutations in patients of Argentina. J Pediatr Hematol Oncol. 2004;26:656-660.
46. Mouy R, FischerA, Vilmer E, Seger RA, Griscelli C. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr. 1989;114:555-560.